UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported)
|
April
25, 2017
|
NAVIDEA BIOPHARMACEUTICALS, INC.
|
(Exact name of registrant as specified in its charter)
|
Delaware
|
001-35076
|
31-1080091
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
5600 Blazer Parkway, Suite 200, Dublin, Ohio
|
43017
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(614)
793-7500
|
|
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
|||
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
|
|
Item 5.02. Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
2016 Bonus Awards for Executive Officers
On
April 25, 2017, the Compensation, Nominating and Governance
(“CNG”) Committee of the Board of Directors of Navidea
Biopharmaceuticals, Inc. (the “Company”) determined to
pay a cash bonus to each of Michael M. Goldberg, M.D., the
Company’s President and Chief Executive Officer, in the
amount of $110,684.93, and Jed A. Latkin, the Company’s
Interim Chief Operating Officer and Chief Financial Officer, in the
amount of $122,903.23 for the year ended December 31, 2016. As
previously reported in the Company’s Current Report on Form
8-K filed with the Securities and Exchange Commission on February
10, 2017, the CNG Committee had deferred determination of 2016
bonus awards to each of Dr. Goldberg and Mr. Latkin pending the
closing of the Company’s sale of certain assets to Cardinal
Health 414, LLC, which occurred on March 3, 2017.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Navidea
Biopharmaceuticals, Inc.
|
|
|
|
|
|
|
|
Date:
May 1, 2017
|
By:
|
/s/ Jed
A. Latkin
|
|
|
Jed A.
Latkin, Interim Chief Operating Officer
and
Interim Chief Financial Officer
|